Publications by authors named "K L Saving"

Background: Adults with sickle cell disease (SCD) suffer early mortality and high morbidity. Many are not affiliated with SCD centers, defined as no ambulatory visit with a SCD specialist in 2 years. Negative social determinants of health (SDOH) can impair access to care.

View Article and Find Full Text PDF

Background: Sickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization. Until recently, hydroxyurea was the only disease-modifying treatment for this life-threatening disease and has remained the only option for children younger than 5 years. Evidence-based guidelines recommend using a shared decision-making (SDM) approach for offering hydroxyurea to children with SCA (HbSS or HbS/β0 thalassemia) aged as early as 9 months.

View Article and Find Full Text PDF
Article Synopsis
  • Sickle cell disease (SCD) affects over 100,000 people in the USA and millions globally, with hydroxyurea being the main treatment to improve patient outcomes.
  • Due to individual differences in drug response, the traditional method of starting hydroxyurea at a standard dose often leads to inadequate treatment for many patients.
  • The Hydroxyurea Optimization through Precision Study (HOPS) is a multi-center trial aimed at comparing standard dosing to a personalized, pharmacokinetics (PK)-guided approach to determine which method works better for children with SCD.
View Article and Find Full Text PDF

Sickle cell disease is an autosomal recessive disorder with significant global impact. This disorder causes the production of a dysfunctional hemoglobin, which leads to sickling of erythrocytes and ultimately hemolysis, endothelial dysfunction, vaso-occlusion, and sterile inflammation. These cellular level processes produce end-organ changes that ultimately result in specific risks and preventive care needs, unique emergency situations, and long-term complications for patients.

View Article and Find Full Text PDF

National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases.

View Article and Find Full Text PDF